Source: Annual Congress 2001 - Pulmonary hypertension: effect of iloprost
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. J. Allcock, M. B. Day, S. Adwani, H. H. Bain, P. A. Corris (Newcastle upon Tyne, United Kingdom). Nebulised Iloprost for pulmonary arterial hypertension associated with congenital heart disease: one centre's experience. Eur Respir J 2001; 16: Suppl. 31, 2166

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease Source: Eur Respir Rev 2009; 18: 154-161 Year: 2009 Changing demographics of pulmonary arterial hypertension in congenital heart disease Source: Eur Respir Rev 2010 19: 308-313 Year: 2010 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Bosentan treatment for pulmonary arterial hypertension related to congenital heart disease: real-world clinical experience in Spain Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Pulmonary arterial hypertension: a comparison between children and adults Source: Eur Respir J 2011; 37: 665-677 Year: 2011 Effect of sitaxentan in patients with pulmonary arterial hypertension associated to congenital heart diseases Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Pulmonary hypertension in children Source: Eur Respir Mon 2012; 57: 94-107 Year: 2012 Initial experience of sildenafil in patients with congenital heart disease (CHD) associated pulmonary arterial hypertension (PAH) Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 Pulmonary arterial hypertension in children Source: Eur Respir J 2003; 21: 155-176 Year: 2003 Pulmonary arterial hypertension associated with congenital heart disease Source: Eur Respir Rev 2012 21: 328-337 Year: 2012 The effect of 12 months Bosentan treatment on congenital heart disease associated pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 Characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease in the French PAH registry Source: Annual Congress 2011 - Clinical characteristics of patients with pulmonary hypertension Year: 2011 Efficacy and safety of oral bosentan in patients with Down‘s syndrome and pulmonary arterial hypertension due to congenital heart disease Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH Year: 2012 Pulmonary hypertension in left heart, respiratory and trombo-embolic pulmonary disease Source: International Congress 2015 – Pulmonary hypertension Year: 2015 Pulmonary arterial hypertension masquerading as severe refractory asthma Source: Eur Respir J 2008; 32: 513-516 Year: 2008 Inhaled iloprost for patients with pulmonary arterial hypertension and right heart failure Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Hemodynamic assessment of pulmonary hypertension in grown-up congenital heart disease Source: Annual Congress 2012 - Pulmonary circulation: end-points and biomarkers Year: 2012 Efficacy of exercise training in congenital heart disease associated pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH Year: 2012 Metformin added to bosentan therapy in patients with pulmonary arterial hypertension associated with congenital heart defects: a pilot study Source: ERJ Open Res, 4 (3) 00060-2018; 10.1183/23120541.00060-2018 Year: 2018